

NEWSLETTER

CHEMICAL & PHARMACEUTICAL 9 - 15 March 2026



China unveils self-developed, cutting-edge carbon fiber material

China unveiled an independently developed SYT80 (T1200-grade) ultra-high-strength carbon fiber material on March 11, marking a major breakthrough in the country's advanced materials sector and filling a gap in the global market. The new product was developed by a subsidiary of China National Building Material Group (CNBM), a Beijing-based centrally administered State-owned enterprise. **(China Daily)**

100,000-ton Specialty Lithium Iron Phosphate Project Receives Energy Conservation Approval

The Sichuan Provincial Development and Reform Commission officially issued the "Report on the Review Opinions of the Energy Conservation Report for the 100,000-ton/year Specialty Iron Phosphate and 100,000-ton/year Specialty Lithium Iron Phosphate Project", approving the energy conservation report in principle. This marks another key step forward in the project's preliminary approval process. **(ChemNet Chemical Headlines)**

Dow Chemical Raises Prices Repeatedly

Global chemical giant Dow Chemical (DOW) has issued a series of price adjustment announcements in response to rising costs of upstream raw materials, energy, and the supply chain. It has raised prices for all its silicone products (including D4, raw rubber, 107 silicone, silicone oil, etc.) in Greater China by 5%-15%, and uniformly increased prices for polyether polyols in the Asia-Pacific region by \$300/ton. **(ChemNet Chemical Headlines)**

Newly developed 'NeuroWorm' a breakthrough for neural monitoring

Chinese scientists have developed "NeuroWorm," a flexible, thread-like device that can move freely inside the body to monitor and stimulate neural activity. Demonstrated in mice, it enables dynamic, large-area tracking of brain and muscle signals with a single implantation. Equipped with high-density micro-sensors, the innovation improves precision and reduces the need for multiple invasive surgeries. **(China Daily)**

China's national medical insurance catalog contains over 230 anticancer drugs

China's national medical insurance catalog now includes over 230 anticancer drugs, covering more than 20 common cancer types. Recent additions, some made within a year of approval, reflect an accelerated inclusion of effective treatments. This progress has contributed to raising the national five-year cancer survival rate from 33.3% to 43.7% in the past decade. **(Xinhua)**